Given that TGF-β is a multifunctional cytokine that drives inflammation and pulmonary fibrosis [58, 59], we hypothesized that anti-TGF-β might reduce immune pneumonia and fibrosis induced by anti-PD-1 and EGFR-TKI treatment. This evidence concerns the gene PDCD1 and pulmonary fibrosis.